David Fox III
Senior Manager - Structural Biology & Head of US Crystallography UCB
Dr. David Fox III leads UCB’s US Crystallography team and serves as Senior Manager of Structural Biology, driving structure-based drug discovery for across a wide range of disease areas. With over 20 years of experience in structural biology and protein biochemistry, David has solved structures of challenging multi-protein complexes and managed collaborations spanning early to late-stage discovery programs. His career includes postdoctoral research at the NIH on DNA damage recognition and repair, and roles at the University of Washington and Beryllium. David earned his Ph.D. in Biochemistry from the University of Washington.
Seminars
With a variety of techniques available in the structure-based drug design toolbox, each with its own advantages and limitations, optimal drug design requires moving beyond single-technique approaches to cohesive, multi-modal design workflows. This workshop will provide attendees with practical insights into integrating multiple methods, including leveraging the strengths of X-ray crystallography, NMR, Cryo-EM, Cryo-ET, HDX-MS, and computational tools to optimize small molecules, biologics, and complex targets.
Highlights include:
Examine the strengths, limitations, and practical applications of each technique including X-ray crystallography, Cryo-EM, Cryo-ET, NMR, HDX-MS, and biophysical assays, for small molecule and biologics discovery
Learn strategies to integrate multiple structural and computational data sources, manage conformational heterogeneity, and balance experimental versus predictive insights
Explore real-world case studies demonstrating how multi-technique approaches accelerate hit-to-lead optimization, improve candidate selection, and inform beyond potency design
This session is ideal for structural biologists, computational chemists, medicinal chemists, and drug discovery scientists seeking to implement an integrative, technique-agnostic approach to make informed decisions in structure-based drug design.
